ALS (Amyotrophic Lateral Sclerosis) — Deal Benchmarks & Valuation
Market Analysis
ALS (Amyotrophic Lateral Sclerosis) is one of the most actively transacted indications in neurology licensing. Phase 2 deals for als (amyotrophic lateral sclerosis) carry a median total deal value of $3.9B, with upfront payments ranging from $214M to $659M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for als (amyotrophic lateral sclerosis) deals allocate $1.1B to development milestones, $1.2B to regulatory milestones, and $1.1B to commercial milestones. Royalty rates range from 13.3% to 21.3% at the base tier, with tiered escalation reaching 17.3%-25.3% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for als (amyotrophic lateral sclerosis) licensing?
What royalty rates are standard for als (amyotrophic lateral sclerosis) deals?
How are als (amyotrophic lateral sclerosis) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.